Search The Medical Knowledge Base

Drug Details

ABILIFY Tablets

• Drug Class Description
  Antipsychotics
• Generic Name
  Aripiprazole
• Presentation
  ABILIFY 5 mg tablet contains 5 mg of aripiprazole. ABILIFY 10 mg tablet contains 10 mg of aripiprazole. ABILIFY 15 mg tablet contains 15 mg of aripiprazole. ABILIFY 30 mg tablet contains 30 mg of aripiprazole.
• Description
  ABILIFY 5 mg tablets are rectangular and blue, engraved with A-007 and 5 on one side. ABILIFY 10 mg tablets are rectangular and pink, engraved with A-008 and 10 on one side. ABILIFY 15 mg tablets are round and yellow, engraved with A-009 and 15 on one side. ABILIFY 30 mg tablets are round and pink, engraved with A-011 and 30 on one side.
• Indications
  ABILIFY is indicated for the treatment of schizophrenia.
• Adult Dosage
  

  Oral use.

  Schizophrenia:

  The recommended starting dose for ABILIFY is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a onceaday schedule without regard to meals. For the oral solution, a calibrated, propylene measuring cup is included in the carton.

  ABILIFY is effective in a dose range of 10 to 30 mg/day (i.e. 10 to 30ml solution/day). Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.

  Manic episodes:

  The recommended starting dose for ABILIFY is 15 mg (i.e. 15ml solution/day) administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy. Some patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg (i.e. 30ml solution/day).

  Recurrence prevention of manic episodes in Bipolar I Disorder:

  For preventing recurrence of manic episodes in patients who have been receiving aripiprazole, continue therapy at the same dose. Adjustments of daily dosage, including dose reduction should be considered on the basis of clinical status.

  The orodispersible tablet should be placed in the mouth on the tongue, where it will rapidly disperse in saliva. It can be taken with or without liquid. Removal of the intact orodispersible tablet from the mouth is difficult. Since the orodispersible tablet is fragile, it should be taken immediately on opening the blister. Alternatively, disperse the tablet in water and drink the resulting suspension.

  ABILIFY oral solution and orodispersible tablets may be used as an alternative to ABILIFY tablets for patients who have difficulty swallowing ABILIFY tablets.

  Patients with hepatic impairment: no dosage adjustment is required for patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment.

  Patients with renal impairment: no dosage adjustment is required in patients with renal impairment.

  Gender: no dosage adjustment is required for female patients as compared to male patients.

  Smoking status: according to the metabolic pathway of ABILIFY no dosage adjustment is required for smokers.

  When concomitant administration of potent CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased.

  When concomitant administration of potent CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the combination therapy, the aripiprazole dose should then be reduced to the recommended dose.

• Child Dosage
  

  There is no experience in children and adolescents under 18 years of age.

• Elderly Dosage
  

  The effectiveness of ABILIFY in the treatment of schizophrenia in patients 65 years of age or older has not been established. Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant.

• Contra Indications
  

  Hypersensitivity to the active substance or to any of the excipients.

• Special Precautions
  

  During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.

  The occurrence of suicidal behaviour is inherent in psychotic illnesses and in some cases has been reported early after initiation or switch of antipsychotic therapy, including treatment with aripiprazole. Close supervision of high-risk patients should accompany antipsychotic therapy. Results of an epidemiological study found that there was no increased risk of suicidality with aripiprazole compared to other antipsychotics among patients with bipolar disorder.

  Cardiovascular disorders: Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolaemia, and treatment with antihypertensive medications) or hypertension, including accelerated or malignant.

  Conduction abnormalities: In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo. As with other antipsychotics, aripiprazole should be used with caution in patients with a family history of QT prolongation.

  Tardive Dyskinesia: in clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on ABILIFY, dose reduction or discontinuation should be considered. These symptoms can temporarily deteriorate or can even arise after discontinuation of treatment.

  Neuroleptic Malignant Syndrome (NMS): NMS is a potentially fatal symptom complex associated with antipsychotic medicinal products. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotic medicinal products, including ABILIFY, must be discontinued.

  Seizure: in clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures.

  Elderly patients with dementia-related psychosis:

  Increased mortality : in three placebo-controlled trials (n= 938; mean age: 82.4 years; range: 5699 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo. The rate of death in aripiprazole-treated patients was 3.5% compared to 1.7% in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature.

  Cerebrovascular adverse events: in the same trials, cerebrovascular adverse events (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 7888 years). Overall, 1.3% of aripiprazole-treated patients reported cerebrovascular adverse events compared with 0.6% of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse events in patients treated with aripiprazole.

  ABILIFY is not approved for the treatment of dementia-related psychosis.

  Hyperglycaemia and Diabetes Mellitus: hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotic agents, including ABILIFY. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse events (including diabetes) or in abnormal glycaemia laboratory values compared to placebo. Precise risk estimates for hyperglycaemia-related adverse events in patients treated with ABILIFY and with other atypical antipsychotic agents are not available to allow direct comparisons. Patients treated with any antipsychotic agents, including ABILIFY, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.

  Weight gain: weight gain is commonly seen in schizophrenic patients due to co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style, and might lead to severe complications. Weight gain has been very rarely reported post-marketing among patients prescribed ABILIFY. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain.

  Dysphagia: oesophageal dysmotility and aspiration have been associated with antipsychotic drug use, including ABILIFY. Aripiprazole and other antipsychotic drugs should be used cautiously in patients at risk of aspiration pneumonia.

  Intolerance:

  Tablets: The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption should not take the oral tablets.

  Orodispersible tablets:The orodispersible tablets contain aspartame. Aspartame is a source of phenylalanine which may be harmful for people with phenylketonuria.

  Oral solution

  The oral solution contains fructose, sucrose, methyl parahydroxybenzoate and propyl parahydroxybenzoate.

  Patients with the following should not take the oral solution:

  • rare hereditary problems of fructose intolerance
  • glucose-galactose malabsorption
  • sucrase-isomaltase insufficiency

  The oral solution contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).

  Hypersensitivity:

  As with other medications, hypersensitivity reactions characterised by allergic symptoms, may occur with aripiprazole.

• Interactions
  

  Due to its α₁adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.

  Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is taken in combination with alcohol or other CNS medicinal products with overlapping undesirable effects such as sedation.

  If aripiprazole is administered concomitantly with medicines known to cause QT prolongation or electrolyte imbalance, caution should be used.

  Potential for other medicinal products to affect ABILIFY:

  A gastric acid blocker, the H₂ antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant.

  Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.

  In a clinical trial in healthy subjects, a potent inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107%, while C_max was unchanged. The AUC and C_max of dehydro-aripiprazole, the active metabolite, decreased by 32% and 47%. ABILIFY dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of ABILIFY with quinidine occurs. Other potent inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.

  In a clinical trial in healthy subjects, a potent inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and C_max by 63% and 37%, respectively. The AUC and C_max of dehydro-aripiprazole increased by 77% and 43%, respectively. In CYP2D6 poor metabolisers, concomitant use of potent inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolisers. When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with ABILIFY, potential benefits should outweigh the potential risks to the patient. When concomitant administration of ketoconozole with ABILIFY occurs, ABILIFY dose should be reduced to approximately one-half of its prescribed dose. Other potent inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors, may be expected to have similar effects and similar dose reductions should therefore be applied.

  Upon discontinuation of the CYP2D6 or 3A4 inhibitor, the dosage of ABILIFY should be increased to the level prior to the initiation of the concomitant therapy.

  When weak inhibitors of CYP3A4 (e.g., diltiazem or escitalopram) or CYP2D6 are used concomitantly with ABILIFY, modest increases in aripiprazole concentrations might be expected.

  Following concomitant administration of carbamazepine, a potent inducer of CYP3A4, the geometric means of C_max and AUC for aripiprazole were 68% and 73% lower, respectively, compared to aripiprazole 30 mg administered alone. Similarly, for dehydro-aripiprazole the geometric means of C_max and AUC after carbamazepine co-administration were 69% and 71% lower, respectively, than those following treatment with aripiprazole alone.

  ABILIFY dose should be doubled when concomitant administration of ABILIFY occurs with carbamazepine. Other potent inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects and similar dose increases should therefore be applied. Upon discontinuation of potent CYP3A4 inducers, the dosage of ABILIFY should be reduced to the recommended dose.

  When either valproate or lithium were administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations.

  Potential for ABILIFY to affect other medicinal products:

  In clinical studies, 1030 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3methoxymorphinan ratio), 2C9 (warfarin), 2C19 (omeprazole), and 3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro. Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.

  When aripiprazole was administered concomitantly with either valproate or lithium, there was no clinically important change in valproate or lithium concentrations.

• Adverse Drug Reactions
  

  The following undesirable effects occurred more often ( > 1/100 ) than placebo, or were identified as possibly medically relevant adverse reactions (*):

  The frequency listed below is defined using the following convention:

  common ( > 1/100, < 1/10 ) and uncommon ( > 1/1,000, < 1/100 ).

  Cardiac disorders Uncommon: tachycardia*

  Nervous System disorders Common: extrapyramidal disorder, akathisia, tremor, dizziness, somnolence, sedation, headache

  Eye disorders Common: blurred vision

  Gastrointestinal disorders Common: dyspepsia, vomiting, nausea, constipation, salivary hypersecretion

  Vascular disorders Uncommon: orthostatic hypotension*

  General disorders and administration site conditions Common: fatigue

  Psychiatric disorders Common: restlessness, insomnia, anxiety Uncommon: depression*

  Extrapyramidal symptoms (EPS): Schizophrenia - in a long term 52-week controlled trial, aripiprazole-treated patients had an overall-lower incidence (25.8%) of EPS including parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3%). In a long term 26-week placebo-controlled trial, the incidence of EPS was 19% for aripiprazole-treated patients and 13.1% for placebo-treated patients. In another long-term 26-week controlled trial, the incidence of EPS was 14.8% for aripiprazole-treated patients and 15.1% for olanzapine-treated patients. Manic episodes in Bipolar I Disorder - in a 12-week controlled trial, the incidence of EPS was 23.5% for aripiprazole-treated patients and 53.3% for haloperidol-treated patients. In another 12-week trial, the incidence of EPS was 26.6% for patients treated with aripiprazole and 17.6% for those treated with lithium. In the long term 26-week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2% for aripiprazole-treated patients and 15.7% for placebo-treated patients.

  In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1% with aripiprazole and 3.2% with placebo. In schizophrenia patients the incidence of akathisia was 6.2% with aripiprazole and 3.0% with placebo.

  Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory parameters revealed no medically important differences. Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5% of aripiprazole treated patients as compared to 2.0% of patients who received placebo.

  Other findings:

  Undesirable effects known to be associated with antipsychotic therapy and also reported during treatment with aripiprazole include neuroleptic malignant syndrome, tardive dyskinesia, seizure, cerebrovascular adverse events and increased mortality in elderly demented patients, hyperglycaemia and diabetes mellitus.

  Post-Marketing:

  The following adverse events have also been reported during post-marketing surveillance. The frequency of these events is considered not known (cannot be estimated from the available data).

   

  Investigations:	Creatine phosphokinase increase, blood glucose fluctuation or increase, glycosylated haemoglobin increase
  Cardiac disorders:	QT prolongation, ventricular arrhythmias, sudden unexplained death, cardiac arrest, torsades de pointes, bradycardia
  Blood and the lymphatic system disorders:	Leucopenia, neutropenia, thrombocytopenia
  Nervous system disorders:	Speech disorder, Neuroleptic Malignant Syndrome (NMS), grand mal convulsion
  Respiratory, thoracic and mediastinal disorders:	Oropharyngeal spasm, laryngospasm, aspiration pneumonia
  Gastrointestinal disorders:	Pancreatitis, dysphagia, abdominal discomfort, stomach discomfort, diarrhoea
  Renal and urinary disorders:	Urinary incontinence, urinary retention
  Skin and subcutaneous tissue disorders:	Rash, photosensitivity reaction, alopecia, hyperhidrosis
  Musculoskeletal, connective tissue and bone disorders:	Rhabdomyolysis, myalgia, stiffness
  Endocrine disorders:	Hyperglycaemia, diabetes mellitus, diabetic ketoacidosis, diabetic hyperosmolar coma
  Metabolism and nutrition disorders:	Weight gain, weight decrease, anorexia, hyponatremia
  Vascular disorders:	Syncope, hypertension, thromboembolic events
  General disorders and administration site conditions:	Temperature regulation disorder (e.g. hypothermia, pyrexia), chest pain, peripheral oedema
  Immune system disorders:	Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritis, or urticaria)
  Hepato-biliary disorders:	Jaundice, hepatitis, increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transferase (GGT) & alkaline phosphatase
  Reproductive system and breast disorders:	Priapism
  Psychiatric disorders:	Agitation, nervousness, anxiety, suicide attempt, suicidal ideation, and completed suicide